Know Cancer

or
forgot password

Tumor Immunity in Neurologically Normal Patients


N/A
18 Years
N/A
Open (Enrolling)
Both
Healthy

Thank you

Trial Information

Tumor Immunity in Neurologically Normal Patients


Inclusion Criteria:



1. Males and females ages 25 -75

2. If leukapheresis:

Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if
tested* HIV antibody negative if tested* VDRL negative if tested* No known IV drug
users HgB > 8.5 WBC > 3,800 Platelets > 120,000 INR < 2 (verified only if clinically
indicated)

3. If large blood draw (1/2 to 1 unit) in lieu of leukapheresis:

Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if tested*
HIV antibody negative if tested* VDRL negative if tested* No known IV drug users HgB >
10.0 WBC > 3,800 Platelets > 120,000 INR < 2 (verified only if clinically indicated)

Exclusion Criteria:

No known neurologic disease 2. No known CNS metastasis on clinical exam 3. No chemotherapy
within 1 month 4. No NYHA class III/IV status 5. No pulmonary disease which limits daily
activities 6. No anticoagulation therapy

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Assessment of PND antibody titer, CTL activity, and clinical data in neurologically normal patients with SCLC and gynecologic tumors, with tumors unrelated to PNDs, and in normal control patients.

Outcome Time Frame:

Duration of study

Safety Issue:

No

Principal Investigator

Robert Darnell, MD, PHD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rockefeller University

Authority:

United States: Institutional Review Board

Study ID:

RDA-0269

NCT ID:

NCT00481637

Start Date:

March 1998

Completion Date:

December 2015

Related Keywords:

  • Healthy
  • To evaluate immune responses in neurologically normal cancer patients

Name

Location

Rockefeller University HospitalNew York, New York  10021-6399